Hidradenitis suppurativa associated with sorafenib initiation

Dermatol Online J. 2019 Jun 15;25(6):13030/qt1s2016td.

Abstract

Sorafenib is a multi-kinase inhibitor approved for the treatment of renal cell and hepatocellular carcinoma. Adverse cutaneous reactions are a very common side effect of the medication. We report the development of hidradenitis suppurativa (HS) in a patient after initiation of treatment with sorafenib. HS is marked by recurrent deep painful nodules, fluctuant abscesses, and draining sinus tracts most frequently occurring in the groin and axilla. To our knowledge, sorafenib-induced HS in the axillary and inguinal skin folds has not been previously reported.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents / adverse effects*
  • Axilla
  • Deprescriptions
  • Hidradenitis Suppurativa / chemically induced*
  • Humans
  • Male
  • Sorafenib / adverse effects*
  • Thyroid Cancer, Papillary / drug therapy*
  • Thyroid Neoplasms / drug therapy*

Substances

  • Antineoplastic Agents
  • Sorafenib